Their findings described that in PDA, polymorphisms in CYP1B1 might be related with K-ras activation pathways.50 Another research group examined CYP1B1 polymorphisms in 60 castration-resistant prostate cancer (CRPC) patients treated with docetaxel. This evidence concerns the gene CYP1B1 and Patent ductus arteriosus.